Recent Updates
Recently added Catalysts
SRPT Positive Sentiment

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Key Takeaway: Sarepta Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will include a Q&A session and will be available via live webcast. Sarepta aims to advance precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy.
Price reaction · baseline $21.31 (2026-01-02 close) · hit pre-market · clean, no other SRPT news in the window
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sarepta Therapeutics is recognized as a leader in precision genetic medicine.
  • The company is actively engaging with investors at a major healthcare conference.
  • The presentation will be accessible via a live webcast, enhancing transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 12, 2026 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T.
The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website athttps://investorrelations.sarepta.com/events-presentationsand will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Frequently Asked Questions

When will Sarepta present at the J.P. Morgan Conference?

Sarepta will present on January 12, 2026, at 12:00 p.m. E.T.

How can I access the Sarepta presentation?

The presentation will be webcast live on Sarepta's investor relations website.

What is the focus of Sarepta Therapeutics?

Sarepta focuses on precision genetic medicine for rare diseases.

Will there be a Q&A session after the presentation?

Yes, a Q&A session will follow the presentation starting at 12:20 p.m. E.T.

Last updated: Jan 5, 2026